生物谷(833266) - 2023 Q4 - 年度业绩预告

Financial Performance - The company expects a net loss attributable to shareholders of between -13.13 million and -10.20 million yuan for the fiscal year 2023, compared to a loss of 49.17 million yuan in the same period last year [4]. - The basic earnings per share for the reporting period is projected to be -0.09 yuan [5]. - Other income decreased by 12.36 million yuan to 12.54 million yuan compared to the previous year, primarily due to a reduction in deferred government subsidies [5]. - The company has recognized a bad debt provision of 43.69 million yuan for the current period, down from 89.95 million yuan in the previous period, with a cumulative provision of 133.64 million yuan [5]. - The financial data presented is preliminary and has not been audited, and the final figures will be disclosed in the official 2023 annual report [6]. Business Development - The company is actively developing blank markets and enhancing brand promotion efforts, which has contributed to an increase in sales revenue [5]. - The company is in communication with shareholders regarding the resolution of fund occupation issues [5].